SCM
TBPH icon

Segantii Capital Management’s Theravance Biopharma TBPH Stock Holding History

Segantii Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,500
Closed -$55K – 235
2017
Q1 		$55K Buy
+1,500
New +$47.9K 0.01% 265

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Segantii Capital Management's TBPH Position: Q2 2017 in Review

Segantii Capital Management sold out of Theravance Biopharma (TBPH) in Q2 2017, closing a stake of 1,500 shares — an estimated $55K sold.

Segantii Capital Management first reported a position in TBPH in Q1 2017 and held it in 1 quarter. The position peaked at $55K in Q1 2017. 94 funds tracked by Wall St. Rank hold TBPH as of Q2 2017.

  • Segantii Capital Management reported no remaining Theravance Biopharma position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,500 Theravance Biopharma shares in Q2 2017, an estimated $55K.
  • Segantii Capital Management first reported a position in Theravance Biopharma in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Theravance Biopharma position peaked at $55K in Q1 2017.
  • 94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.